Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic hUCB Infusion in Children with Cerebral Palsy
NCT06377982Phase 1Not yet recruiting
- Sponsor
- StemCyte Inc.
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, randomised, double-blind trial of allogeneic human umbilical cord blood in cerebral palsy (CP) (2 arms), sponsored by StemCyte Inc. Primary endpoint: Treatment-Emergent Adverse Events at 56 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
allogeneic human umbilical cord blood
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT06377982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06377982.